Resiniferatoxin

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain	2023/01/25	NCT05695339	Phase 1	Recruiting	National Institutes of Health Clinical Center (CC)
Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee	2022/07/08	NCT05449132	Phase 3	Completed	Grünenthal GmbH
Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee	2022/05/17	NCT05377489	Phase 3	Active, not recruiting	Grünenthal GmbH
Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis	2022/02/21	NCT05248386	Phase 3	Completed	Grünenthal GmbH
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer	2021/10/05	NCT05067257	Phase 2	Suspended	Sorrento Therapeutics, Inc.
Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis	2021/05/13	NCT04885972	Phase 2	Active, not recruiting	Sorrento Therapeutics, Inc.
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain	2020/10/01	NCT04572776	Phase 3	Withdrawn	Sorrento Therapeutics, Inc.
Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed	2020/05/13	NCT04386980	Phase 3	Withdrawn	Sorrento Therapeutics, Inc.
A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee	2019/08/05	NCT04044742	Phase 3	Withdrawn	Sorrento Therapeutics, Inc.
Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis	2018/05/31	NCT03542838	Phase 1	Completed	Sorrento Therapeutics, Inc.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

NIH Scientists Report Breakthrough Plant-Derived Therapy Reduces Intractable Cancer Pain by 38%

a month ago

NIH scientists conducted a first-in-human clinical trial of resiniferatoxin (RTX), a plant-derived molecule that reduced worst pain intensity by 38% and opioid use by 57% in advanced cancer patients.

Grünenthal Initiates Phase I Trial of Nociceptin Receptor Agonist for Chronic Pain

8 months ago

Grünenthal has dosed the first participants in a Phase I trial of a novel nociceptin (NOP) receptor agonist.

Resiniferatoxin Receives FDA Breakthrough Therapy Designation for Osteoarthritis Pain

9 months ago

Grünenthal's resiniferatoxin (RTX), a non-opioid therapy, has been granted Breakthrough Therapy Designation by the FDA for knee osteoarthritis pain.

AI-Powered Research

Premium Access